|
Adverse events within 7 days of administration; study participants aged 18-64 years from COV001, COV002, and COV003 studies | ||
|
Adverse event reported |
Dose 1 (%) |
Dose 2 (%) |
|
Local erythema |
2.6 |
1.1 |
|
Local swelling |
2.9 |
0.9 |
|
Pain at injection site |
60.3 |
34.4 |
|
Local pruritus |
6.5 |
4.2 |
|
Fatigue |
64.6 |
43.0 |
|
Headache |
61.1 |
38.3 |
|
Chills |
37.2 |
6.5 |
|
Nausea |
23.9 |
9.7 |
|
Fever |
11.6 |
0.7 |
|
Myalgia |
52.3 |
25.6 |
|
Arthralgia |
28.0 |
11.6 |
|
Adverse events within 7 days of administration; study participants aged ≥65 years from COV001, COV002, and COV003 studies | ||
|
Adverse event reported |
Dose 1 (%) |
Dose 2 (%) |
|
Local erythema |
2.3 |
0.4 |
|
Local swelling |
2.0 |
0.8 |
|
Pain at injection site |
22.8 |
10.2 |
|
Local pruritus |
3.5 |
2.3 |
|
Fatigue |
40.9 |
27.0 |
|
Headache |
31.8 |
19.9 |
|
Chills |
10.8 |
2.0 |
|
Nausea |
8.0 |
5.5 |
|
Fever |
1.0 |
0.0 |
|
Myalgia |
22.6 |
13.7 |
|
Arthralgia |
13.0 |
7.4 |
|
Adapted from Lancet. 2021 Jan 9;397(10269):99-111. and Product Monograph: AstraZeneca COVID-19 Vaccine, ChAdOx1-S [recombinant]. | ||